{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T06:00:32Z","timestamp":1781071232967,"version":"3.54.1"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Muscle-specific tyrosine kinase antibody-positive myasthenia gravis (MuSK-MG), a subtype of myasthenia gravis (MG), follows an acute and severe disease course with suboptimal responses to standard treatments. Ofatumumab is a fully humanized anti-CD20 monoclonal antibody that induces potent and sustained B-cell depletion. Nonetheless, there are few reports on its use in sequential therapy failure after the failure of conventional drug treatment in MuSK-MG patients, especially in the Asian population. We report a 32-year-old female patient with anti-MuSK antibody-positive myasthenia gravis who was treated with ofatumumab as a rescue therapy after failing multiple treatments such as intravenous immunoglobulin (IVIG), plasma exchange, and efgartigimod, progressed to a crisis state necessitating prolonged mechanical ventilation. After the addition of ofatumumab to the combination of tacrolimus and corticosteroids, the clinical symptoms were significantly improved, the patient was successfully weaned from ventilator-assisted ventilation, the bulbar function was improved, and the limb muscle strength was significantly restored, and the patient was finally discharged uneventfully. This case is the first report of ofatumumab successfully treating refractory MuSK-MG in China, providing real-world evidence for its pivotal role in the treatment sequence. It also suggests that its characteristics, such as subcutaneous administration and low immunogenicity, may render it particularly suitable for high-risk patients, including those with concurrent infections.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1792262","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T05:20:22Z","timestamp":1781068822000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Ofatumumab in refractory anti-muscle-specific tyrosine kinase antibody-positive myasthenia gravis: a case report of successful salvage therapy and mechanistic insights"],"prefix":"10.3389","volume":"17","author":[{"given":"Yikai","family":"Zhang","sequence":"first","affiliation":[{"name":"Guangzhou University of Chinese Medicine","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxi","family":"Li","sequence":"additional","affiliation":[{"name":"Guangzhou University of Chinese Medicine","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guixian","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyou","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00357-4","article-title":"Advances in the understanding of disease mechanisms of autoimmune neuromuscular junction disorders","volume":"21","author":"Huijbers","year":"2022","journal-title":"Lancet Neurol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00297-0","article-title":"Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders","volume":"21","author":"Punga","year":"2022","journal-title":"Lancet Neurol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Nils","year":"2015","journal-title":"Lancet Neurol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000547","article-title":"MuSK myasthenia gravis monoclonal antibodies: Valency dictates pathogenicity","volume":"6","author":"Huijbers","year":"2019","journal-title":"Neurol(R) Neuroimmunol Neuroinflamm"},{"key":"B5","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1093\/qjmed\/hcn152","article-title":"Myasthenic crisis","volume":"102","author":"Chaudhuri","year":"2009","journal-title":"QJM"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn113694-20250120-00041","article-title":"Chinese guidelines for the diagnosis and treatment of myasthenia gravis (2025 edition)","volume":"58","year":"2025","journal-title":"Chin J Neurol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1177\/17562864241261602","article-title":"The safety and efficacy profile of eculizumab in myasthenic crisis: a prospective small case series","volume":"17","author":"Song","year":"2024","journal-title":"Ther Adv Neurol Disord"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1456822","article-title":"Telitacicept in combination with B-cell depletion therapy in MuSK antibody-positive myasthenia gravis: a case report and literature review","volume":"15","author":"Wang","year":"2024","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.str.2025.10.018","article-title":"Muscle-specific tyrosine kinase activation by a peptide-based dimerizer is orientation dependent","volume":"34","author":"Mizutani","year":"2026","journal-title":"Structure"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/cells13060556","article-title":"MuSK myasthenia gravis-potential pathomechanisms and treatment directed against specific targets","volume":"13","author":"Dziadkowiak","year":"2024","journal-title":"Cells"},{"key":"B11","doi-asserted-by":"publisher","first-page":"7219","DOI":"10.1038\/s41598-025-90937-w","article-title":"Efficacy and safety of rituximab in anti-MuSK myasthenia gravis: a systematic review and meta-analysis","volume":"15","author":"Chayanopparat","year":"2025","journal-title":"Sci Rep"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00613","article-title":"Long-lasting rituximab-induced reduction of specific-but not total-IgG4 in MuSK-positive myasthenia gravis","volume":"11","author":"Marino","year":"2020","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2023.137561","article-title":"Promising efficacy of low-dose rituximab in muscle specific kinase antibody positive myasthenia gravis","volume":"818","author":"Yang","year":"2024","journal-title":"Neurosci Lett"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30144-7","article-title":"Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial","volume":"7","author":"Jabbour","year":"2020","journal-title":"Lancet Haematol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2165\/11539590-000000000-00000","article-title":"New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid Malignancies","volume":"25","author":"Robak","year":"2011","journal-title":"BioDrugs"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00212","article-title":"Autoantibody specificities in myasthenia gravis; implications for improved diagnostics and therapeutics","volume":"11","author":"Lazaridis","year":"2020","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1212757","article-title":"Immunotherapies in MuSK-positive myasthenia gravis; an IgG4 antibody-mediated disease","volume":"14","author":"Vakrakou","year":"2023","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00660","article-title":"MuSK-associated myasthenia gravis: clinical features and management","volume":"11","author":"Rodolico","year":"2020","journal-title":"Front Neurol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-024-07577-7","article-title":"Therapeutic challenges and unmet needs in the management of myasthenia gravis: an Italian expert opinion","volume":"45","author":"Mantegazza","year":"2024","journal-title":"Neurol Sci"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11216394","article-title":"New targeted agents in myasthenia gravis and future therapeutic strategies","volume":"11","author":"S\u00e1nchez-Tejerina","year":"2022","journal-title":"J Clin Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s00415-025-13161-6","article-title":"Monitoring anti-rituximab antibodies in myasthenia gravis affects the time to event during rituximab treatment","volume":"272","author":"H\u00e9raud","year":"2025","journal-title":"J Neurol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.102787","article-title":"Comparison of the efficacy and safety of anti-CD20 B cells depleting drugs in multiple sclerosis","volume":"49","author":"Cotchett","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1004795","article-title":"Anti-CD20 therapies in multiple sclerosis: from pathology to the clinic","volume":"14","author":"de S\u00e8ze","year":"2023","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-022-01210-1","article-title":"Autoimmune neurological disorders with IgG4 antibodies: a distinct disease spectrum with unique IgG4 functions responding to anti-B cell therapies","volume":"19","author":"Dalakas","year":"2022","journal-title":"Neurotherapeutics"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0900632","article-title":"Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX","volume":"183","author":"Pawluczkowycz","year":"2009","journal-title":"J Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1280029","article-title":"Normalized circulating Tfh and Th17 associates with improvement in myasthenia gravis treated with ofatumumab","volume":"15","author":"Song","year":"2024","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1792262\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T05:20:24Z","timestamp":1781068824000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1792262\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":26,"alternative-id":["10.3389\/fimmu.2026.1792262"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1792262","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"article-number":"1792262"}}